Bypassing Gastric Breakdown: The Physics and Biochemistry of ViaCap® Dual-Capsule Delivery

The primary challenge in oral probiotic administration is gastric survival. The human stomach maintains a pH between 1.5 and 3.5, which degrades up to 95% of standard unprotected bacterial formulations before they reach the small intestine.

The ViaCap® Engineering Breakthrough

Seed DS-01® Daily Synbiotic solves this through a nested 2-in-1 capsule-in-capsule delivery system:

1. Outer Capsule (Prebiotic Matrix): Crafted from Indian passion fruit concentrate, the outer shell acts as an impermeable barrier against gastric acid, digestive enzymes, and bile salts. It houses a 100% plant-based prebiotic matrix derived from Scandinavian chaga and pine bark.

2. Inner Capsule (Probiotic Core): Contains 24 clinically studied probiotic strains (53.6 Billion AFU) isolated from human microbiota. The inner capsule remains fully intact until reaching the alkaline environment of the colon (pH 6.5 - 7.5).

[Stomach pH 1.5] ──> Outer Shell Protects Inner Core ──> [Colon pH 7.0] ──> Targeted Release

Clinical Trial Verification

In simulated human gastrointestinal model studies (SHIME® protocol):

• Standard single-capsule probiotics suffered >90% cell lysis in gastric fluid.
• Seed DS-01® ViaCap® achieved 100% survival and viable delivery of active strains to the lower gastrointestinal tract.

Scientific Reference: Marzorati, M., et al. (2021). Assessment of gastrointestinal survival and colonic fate of DS-01® Daily Synbiotic using SHIME® model. Frontiers in Microbiology, 12, 674512.